Genetic Signatures (ASX:GSS) said that its Chief Executive Officer, Allison Rossiter, informed the board that she will be leaving the firm in late February 2026 to take on a role with a global pharmaceutical firm, according to a Monday Australian bourse filing.
Jenny Harry and Anne Lockwood will support the management team during the transition.
Its shares fell 9% in recent trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.